No Data
No Data
Express News | With innovation and internationalization, nearly 60% of the performance of 92 biomedical companies in the first half of the year exceeded expectations.
Jafron Biomedical (300529): High growth in 24H1 performance, and the fundamentals continue to recover.
The company has released its performance forecast for the first half of 2024. According to the announcement, the company is expected to achieve a net income attributable to the parent company of 0.527-0.583 billion yuan, an increase of 90%-110% compared to the same period last year. Non-recurring net income is 5.0.
Jafron Biomedical (300529.SZ) releases pre-increase announcement, with an expected net income of 0.527 billion yuan to 0.583 billion yuan in the first half of the year, a year-on-year growth of 90% to 110%.
Jafron Biomedical (300529.SZ) released its 2024 interim performance forecast. It is expected that the net income attributable to the shareholders of the listed company will be between 0.527 billion yuan and 0.583 billion yuan, a year-on-year growth of 90% to 110%; the net income after deducting non-recurring gains and losses will be between 0.501 billion yuan and 0.557 billion yuan, a year-on-year growth of 91% to 112%.
Express News | Jafron Biomedical: expected net income to increase by 90% to 110% year-on-year in the first half of the year.
Jafron Biomedical: 2024 Interim Performance Forecast
Jafron Biomedical (300529): High-speed growth in performance in the first half of the year, and good expansion in various fields in the infusion business.
Performance Summary In July 8th, 2024, the company released its 2024 interim performance forecast, with an expected net income attributable to mother of 5.27 billion to 5.83 billion yuan in the first half of the year, up 90% to 110% year-on-year; non-recurring expenses deduction net income attributable to mother.
No Data